Skip to main content

Treatment of Concominant Conditions Related to DM! (cont.)

 TREATMENT OF CONCOMINANT CONDITIONS RELATED TO DIABETES MELLITUS

  1. Coronary Heart Disease
  2. Dyslipidemia
  3. Hypertension
  4. HIV and AIDS
  5. Antipsychotic Therapy
  6. Hypoglycemia
  7. Diabetic Ketoacidosis (DKA)
  8. Hyperosmolar Hyperglycemic state
  9. Retinopathy
  10. Neuropathy
  11. Foot Ulcers 

3.HYPERTENSION

Uncontrolled blood pressure plays a major role in the development of macrovascular events as well as microvascular complications, including retinopathy and nephropathy in patients with Diabetes Mellitus.

Medications:

There are several other principles regarding the treatment of hypertension in Diabetes patients.

  • Angiotensin-converting enzyme (ACE) inhibitors or Angiotensin II receptor Blockers are recommended as initial therapy because of their beneficial effects on renal function.
  • Combination therapy with ACE Inhibitor and Dihydropyridine calcium channel blockers has shown to reduce cardiovascular morbidity and mortality versus those receiving ACE Inhibitor therapy combined with Thiazide Diuretic.
  • However, thiazide diuretics work synergistically with ACE Inhibitors and angiotensin II receptor blockers and can be added  on for those who fail to reach blood pressure goals with a single agent goal as long as the patients estimated glomerular filtration rate remains at 30mL/min/1.73m2 or higher.
  • Alternatively, a loop diuretic can be used.

Recommended Goals:

  • The ADA recommends that systolic blood pressure goals for patients with DM be individualized but generally set at less than 130mmHg. The diastolic blood pressure goal for patients with DM is less than 80mmHg.
  • It can be expected that most patients require more than one agent to reach blood pressure goal.
  • Renal function and serum potential levels should be monitored closely in all patients taking an ACE inhibitor, Angiotensin II receptor blocker and/or diuretic.

Contraindication:

    • ACE inhibitors and angiotensin II receptor blockers are contraindicated in pregnancy and in those with  bilateral renal therapy.`


4.HUMAN IMMUNODEFICIENCY VIRUS (HIV) and ACQUIRED IMMUNODEFICIENCY SYNDROME (AIDS)

  • Patients with risk factor for diabetes are more likely to develop diabetes when exposed to highly active antiretroviral therapy.
  • Universal screening for all HIV Patients for diabetes is controversial, but most clinicians support screening for those with risk factors, especially if those risk factors include positive family history and central adiposity.
  • Disturbances in glucose homeostasis are known side effects of protease inhibitor therapy.

Medications:

  • Indinavir and Ritonavir block insulin-mediated glucose disposal causing insulin resistance, but Amprenavir and Atazanavir have no effects on this pathway.
  • Indinavir also increases hepatic glucose production and release and causes insulin to lose its ability to suppress hepatic glucose production.
  • Nelfinavir, lopinavir and Saquinavir causes a 25% reduction in beta-cell function, reducing first-phase insulin release.

Contraindications:

  • Drug selection for treating protease inhibitors-induced hyperglycemia should address the mechanism behind the adverse effects.
  • Protease inhibitor therapy should be avoided in patients with pre-existing glucose abnormalities and in those with a first-degree relative with diabetes.
  • Metformin should be used with caution in patients taking the nucleoside reverse transcriptase inhibitors Stavudine, Zidovudine and Didanosine because of an increased risk for lactic acidemia.

5.ANTIPSYCHOTIC DRUG THERAPY

  • An association has been discovered between the second-generation antipsychotics and the development of diabetes.
  • Risk seems to be the highest with Clozapine and Olanzapine, but data are conflicting for Risperidone and Quetiapine.
  • Aripiprazole and Ziprasione for yet have no shown an increased risk for diabetes with their use.

Recommendations:

  • Nutrition and physical activity counselling is recommended for all patients with mental illness who are overweight or obese, especially if they are second generation anti-psychotics.
  • After the therapy, patients' weight should be assessed at weeks 4, 8, and 12 and then every 3 months.
  • In an event of increase in patients weight greater than or equal to 5%, of the patient's baseline weight, the therapeutic adjustment should be considered.
  • For patients who develop worsening glycemia or Dyslipidemia while on antipsychotic therapy, it is recommended that a switch to second generation antipsychotic with less weight gain or diabetes potential be considered. 
Labels:

Comments

Post a Comment

Popular posts from this blog

Diabetes Mellitus: Types!

TYPES OF DIABETES MELLITUS 1. TYPE1 DM Type 1 DM is usually diagnosed before age 30 years, but it can develop at any age. T1DM is an autoimmune disease in which insulin producing B-cells are destroyed. The presence of Human Leucocyte Antigens (HLAs ) is associated with the development of T1DM. In addition, these individuals often develop Islet cell antibodies , Insulin Autoantibodies or Glutamic Acid decarboxylase autoantibodies . At the time of development of diagnosis of T1DM, it is usually believed that most of the patients have 80-90%loss of beta cells. The remaining beta cells function at the diagnosis creates a " HONEYMOON PERIOD" during which the blood glucose levels are easier to control, and smaller amounts of insulin are required. after this, the remaining beta cells function is completely lost, and the patients become completely deficient of insulin and hence require exogenous insulin.  2. TYPE1.5 DM:  Also referred as Latent autoimmune diabetes in Adults (LAD)
Post a Comment
Read more

Diabetes Mellitus: Pharmacotherapy- Gliptins and a-Glycoside Inhibitors!

  PHARMACOTHERAPY:  Medications classifications include:  Sulfonyl Urea's Nonsylfonylurea Secretagogues (a-Glinides) Biguanides Thiazolidinediones a-Glucosidase Inhibitors Dipeptidyl Peptidase-4 Inhibitors (Gliptins) Sodium-glucose co-transporter (SGLT) Inhibitors  Central-Acting Dopamine Agonists Bile Acid Sequestrants Insulin therapy 5. a-GLUCOSIDASE INHIBITORS Acarbose and Miglitol are a-glucosidase inhibitors currently approved in the United States. Mechanism of Action: An enzyme that is along the brush border of the intestine cells called a-glucosidase; breaks down the complex carbohydrates into simple sugars, resulting in absorption. The a-glucosidase inhibitors work by delaying the absorption of carbohydrates from the intestinal tract, which reduces the rise in postprandial glucose levels. Therapy: As a monotherapy , a-glucosidase inhibitors primarily reduce post-prandial glucose excursions.  Clinical Use: FPG concentrations have been decreased by 40-50mg/dL and A1c level
Post a Comment
Read more

GASTRO-ESOPHAGEAL REFLUX DISEASE (GERD)!

MANAGEMENT OF GASTRO-ESOPHAGEAL REFLUX DISEASE  "GERD refers to the endoscopically determined esophagitis or endoscopy-negative reflux disease" . "GERD is the term used to describe any symptomatic clinical condition or histopathological alteration resulting from episodes of reflux of acid, pepsin and occasionally, bile into the esophagus from the stomach". Patients with uninvestigated "reflux-like" symptoms should be managed as patients with uninvestigated dyspepsia. There is currently no evidence that H.pylori should be investigated in patients with GERD. Symptoms: Heartburn is the characteristic symptom of GERD. Acid regurgitation Dysphagia Belching Upper abdominal discomfort Bloating and postprandial fullness Chest pain Hoarseness Cough Complications include: Esophageal ulceration Formation of specialized columnar-lined esophagus at the gastro-esophageal junction known as Barretts Esophagus . Mechanism of Acid Reflux: The mechanism of acid reflux is mu
Post a Comment
Read more